Characterizing autism spectrum disorders by key biochemical pathways

Megha Subramanian, Christina K. Timmerman, Joshua L. Schwartz, Daniel L. Pham, Mollie K Meffert

Research output: Contribution to journalArticle

Abstract

The genetic and phenotypic heterogeneity of autism spectrum disorders (ASD) presents a substantial challenge for diagnosis, classification, research, and treatment. Investigations into the underlying molecular etiology of ASD have often yielded mixed and at times opposing findings. Defining the molecular and biochemical underpinnings of heterogeneity in ASD is crucial to our understanding of the pathophysiological development of the disorder, and has the potential to assist in diagnosis and the rational design of clinical trials. In this review, we propose that genetically diverse forms of ASD may be usefully parsed into entities resulting from converse patterns of growth regulation at the molecular level, which lead to the correlates of general synaptic and neural overgrowth or undergrowth. Abnormal brain growth during development is a characteristic feature that has been observed both in children with autism and in mouse models of autism. We review evidence from syndromic and non-syndromic ASD to suggest that entities currently classified as autism may fundamentally differ by underlying pro- or anti-growth abnormalities in key biochemical pathways, giving rise to either excessive or reduced synaptic connectivity in affected brain regions. We posit that this classification strategy has the potential not only to aid research efforts, but also to ultimately facilitate early diagnosis and direct appropriate therapeutic interventions.

Original languageEnglish (US)
Article number313
JournalFrontiers in Neuroscience
Volume9
Issue numberSEP
DOIs
StatePublished - 2015

Fingerprint

Autistic Disorder
Growth
Genetic Heterogeneity
Brain
Growth and Development
Research
Early Diagnosis
Autism Spectrum Disorder
Clinical Trials
Therapeutics

Keywords

  • Autism spectrum disorders (ASD)
  • ERK signaling
  • MAP kinase signaling system
  • MTOR pathway
  • Neurotrophic factors
  • Protein synthesis

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Characterizing autism spectrum disorders by key biochemical pathways. / Subramanian, Megha; Timmerman, Christina K.; Schwartz, Joshua L.; Pham, Daniel L.; Meffert, Mollie K.

In: Frontiers in Neuroscience, Vol. 9, No. SEP, 313, 2015.

Research output: Contribution to journalArticle

Subramanian, Megha ; Timmerman, Christina K. ; Schwartz, Joshua L. ; Pham, Daniel L. ; Meffert, Mollie K. / Characterizing autism spectrum disorders by key biochemical pathways. In: Frontiers in Neuroscience. 2015 ; Vol. 9, No. SEP.
@article{389db7e391a141958d9aaa5f9f4b2dce,
title = "Characterizing autism spectrum disorders by key biochemical pathways",
abstract = "The genetic and phenotypic heterogeneity of autism spectrum disorders (ASD) presents a substantial challenge for diagnosis, classification, research, and treatment. Investigations into the underlying molecular etiology of ASD have often yielded mixed and at times opposing findings. Defining the molecular and biochemical underpinnings of heterogeneity in ASD is crucial to our understanding of the pathophysiological development of the disorder, and has the potential to assist in diagnosis and the rational design of clinical trials. In this review, we propose that genetically diverse forms of ASD may be usefully parsed into entities resulting from converse patterns of growth regulation at the molecular level, which lead to the correlates of general synaptic and neural overgrowth or undergrowth. Abnormal brain growth during development is a characteristic feature that has been observed both in children with autism and in mouse models of autism. We review evidence from syndromic and non-syndromic ASD to suggest that entities currently classified as autism may fundamentally differ by underlying pro- or anti-growth abnormalities in key biochemical pathways, giving rise to either excessive or reduced synaptic connectivity in affected brain regions. We posit that this classification strategy has the potential not only to aid research efforts, but also to ultimately facilitate early diagnosis and direct appropriate therapeutic interventions.",
keywords = "Autism spectrum disorders (ASD), ERK signaling, MAP kinase signaling system, MTOR pathway, Neurotrophic factors, Protein synthesis",
author = "Megha Subramanian and Timmerman, {Christina K.} and Schwartz, {Joshua L.} and Pham, {Daniel L.} and Meffert, {Mollie K}",
year = "2015",
doi = "10.3389/fnins.2015.00313",
language = "English (US)",
volume = "9",
journal = "Frontiers in Neuroscience",
issn = "1662-4548",
publisher = "Frontiers Research Foundation",
number = "SEP",

}

TY - JOUR

T1 - Characterizing autism spectrum disorders by key biochemical pathways

AU - Subramanian, Megha

AU - Timmerman, Christina K.

AU - Schwartz, Joshua L.

AU - Pham, Daniel L.

AU - Meffert, Mollie K

PY - 2015

Y1 - 2015

N2 - The genetic and phenotypic heterogeneity of autism spectrum disorders (ASD) presents a substantial challenge for diagnosis, classification, research, and treatment. Investigations into the underlying molecular etiology of ASD have often yielded mixed and at times opposing findings. Defining the molecular and biochemical underpinnings of heterogeneity in ASD is crucial to our understanding of the pathophysiological development of the disorder, and has the potential to assist in diagnosis and the rational design of clinical trials. In this review, we propose that genetically diverse forms of ASD may be usefully parsed into entities resulting from converse patterns of growth regulation at the molecular level, which lead to the correlates of general synaptic and neural overgrowth or undergrowth. Abnormal brain growth during development is a characteristic feature that has been observed both in children with autism and in mouse models of autism. We review evidence from syndromic and non-syndromic ASD to suggest that entities currently classified as autism may fundamentally differ by underlying pro- or anti-growth abnormalities in key biochemical pathways, giving rise to either excessive or reduced synaptic connectivity in affected brain regions. We posit that this classification strategy has the potential not only to aid research efforts, but also to ultimately facilitate early diagnosis and direct appropriate therapeutic interventions.

AB - The genetic and phenotypic heterogeneity of autism spectrum disorders (ASD) presents a substantial challenge for diagnosis, classification, research, and treatment. Investigations into the underlying molecular etiology of ASD have often yielded mixed and at times opposing findings. Defining the molecular and biochemical underpinnings of heterogeneity in ASD is crucial to our understanding of the pathophysiological development of the disorder, and has the potential to assist in diagnosis and the rational design of clinical trials. In this review, we propose that genetically diverse forms of ASD may be usefully parsed into entities resulting from converse patterns of growth regulation at the molecular level, which lead to the correlates of general synaptic and neural overgrowth or undergrowth. Abnormal brain growth during development is a characteristic feature that has been observed both in children with autism and in mouse models of autism. We review evidence from syndromic and non-syndromic ASD to suggest that entities currently classified as autism may fundamentally differ by underlying pro- or anti-growth abnormalities in key biochemical pathways, giving rise to either excessive or reduced synaptic connectivity in affected brain regions. We posit that this classification strategy has the potential not only to aid research efforts, but also to ultimately facilitate early diagnosis and direct appropriate therapeutic interventions.

KW - Autism spectrum disorders (ASD)

KW - ERK signaling

KW - MAP kinase signaling system

KW - MTOR pathway

KW - Neurotrophic factors

KW - Protein synthesis

UR - http://www.scopus.com/inward/record.url?scp=84946549812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946549812&partnerID=8YFLogxK

U2 - 10.3389/fnins.2015.00313

DO - 10.3389/fnins.2015.00313

M3 - Article

VL - 9

JO - Frontiers in Neuroscience

JF - Frontiers in Neuroscience

SN - 1662-4548

IS - SEP

M1 - 313

ER -